Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of rhBMP-2/calcium phosphate matrix in women with low bone mineral density at risk of hip fracture
2007-007456-34Phase 2Completed
- Sponsor
- Wyeth
- Start
- Oct 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of dibotermin alfa in osteoporosis and low bone mineral density (3 arms), sponsored by Wyeth. Primary endpoint: Change from baseline in total hip bone mineral density at 12 months. Started Oct 2008; status: completed.
02
Drugs
dibotermin alfa
03
Conditions
osteoporosislow bone mineral density
Beyond the preview
Go deeper on 2007-007456-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007456-34.